These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21119083)

  • 21. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.
    Meyer S; Adam M; Schweiger B; Ilchmann C; Eulenburg C; Sattinger E; Runte H; Schlüter M; Deuse T; Reichenspurner H; Costard-Jäckle A
    Transplantation; 2011 May; 91(9):1031-5. PubMed ID: 21358365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
    Chao DY; Cheng KF; Hsieh YH; Li TC; Wu TN; Chen CY; Tsai CA; Chen JH; Chiu HT; Lu JJ; Su MC; Liao YH;
    Vaccine; 2011 Jan; 29(4):617-23. PubMed ID: 21095255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
    HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R; Amicizia D; Lai PL; Panatto D
    Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
    Tsatsaris V; Capitant C; Schmitz T; Chazallon C; Bulifon S; Riethmuller D; Picone O; Poulain P; Lewin F; Lainé F; Jacqz-Aigrain E; Aboulker JP; Launay O;
    Ann Intern Med; 2011 Dec; 155(11):733-41. PubMed ID: 22147712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.
    Emborg HD; Krause TG; Hviid A; Simonsen J; Mølbak K
    BMJ; 2011 Jan; 344():d7901. PubMed ID: 22277542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi O; Langley JM; Dobson S; Li Y; Law B; Halperin SA;
    Pediatr Infect Dis J; 2011 May; 30(5):402-7. PubMed ID: 21178654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
    Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.
    Schmidt T; Dirks J; Enders M; Gärtner BC; Uhlmann-Schiffler H; Sester U; Sester M
    Eur J Immunol; 2012 Jul; 42(7):1755-66. PubMed ID: 22585549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
    Bickel M; Wieters I; Khaykin P; Nisius G; Haberl A; Stephan C; Von Hentig N; Herrmann E; Doerr HW; Brodt HR; Allwinn R
    AIDS; 2010 Jun; 24(9):F31-5. PubMed ID: 20559034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response to influenza A(H1N1)pdm09 in vaccinated, serologically infected and unaffected pregnant women and their newborns.
    Helmig RB; Maimburg RD; Erikstrup C; Nielsen HS; Petersen OB; Nielsen LP; Hvidman L; Veirum JE; Henriksen TB; Storgaard M
    Acta Obstet Gynecol Scand; 2015 Aug; 94(8):833-9. PubMed ID: 25958884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong.
    Mak GC; Choy PW; Lee WY; Wong AH; Ng KC; Lim W
    J Med Virol; 2010 Nov; 82(11):1809-15. PubMed ID: 20872705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
    Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E
    Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.